N-Acetylcysteine as a Host-Directed Therapy Against Clarithromycin-Resistant Mycobacterium abscessus

Shuqi Yang, Ying Zhang, Jinchuan Xu, Zhenyan Chen, Ren Yang, Yujiao Long, Xuejiao Huang, Juanxi Liu, Huan Huang, Shiqi Xie, Ruiqing Ma, Yajuan Dong, Xiao‐Yong Fan, Zhidong Hu, Feng LiPathogens 2025 · DOI

TL;DR

This study investigates N-acetylcysteine (NAC) as a host-directed therapy for drug-resistant Mycobacterium abscessus infections. NAC significantly reduced bacterial loads in both cell cultures and mouse models by enhancing antioxidant defenses and dampening a key inflammatory pathway (ASK1-MKK3/6-p38 MAPK), suggesting its potential as an adjunctive treatment.

What Problem Does This Paper Address?

Mycobacterium abscessus is a challenging pathogen causing severe lung infections, particularly in individuals with compromised immune systems. A major hurdle in treating these infections is the bacteria's inherent resistance to many antibiotics, including clarithromycin (CLR), a frontline treatment for other non-tuberculous mycobacteria (NTM). Current antibiotic therapies can also disrupt the host's immune balance by increasing oxidative stress, potentially hindering the body's natural defenses. This creates a critical need for alternative or complementary therapeutic strategies that can bolster the host's immune response without exacerbating existing problems. Host-directed therapies, which aim to modulate the host's immune system to fight infection, offer a promising avenue.

Methods

The researchers employed a multi-pronged approach:

  • Screening and Susceptibility Testing: They first isolated a clarithromycin-resistant M. abscessus strain (Mab-4) and determined its minimum inhibitory concentration (MIC) for various drugs, including NAC. They also assessed the synergistic effects of NAC with other antibiotics like clofazimine (CFZ) and CLR.
  • In Vitro Studies: They used THP-1 derived macrophages (a model for human immune cells) infected with M. abscessus. They evaluated the effect of NAC on bacterial load within these cells and assessed its impact on cell viability.
  • In Vivo Studies: Nude mice, which lack T cells and are useful for studying innate immune responses, were infected with M. abscessus. They then treated these mice with NAC, CLR, CFZ, or combinations thereof. Bacterial loads in lungs and spleens were measured, along with histological analysis of lung tissue for inflammation.
  • Molecular Analysis: RNA sequencing (RNA-seq) was used to identify global gene expression changes in NAC-treated mice compared to controls. Western blotting was employed to specifically examine the protein levels and phosphorylation status of key components in the ASK1-MKK3/6-p38 MAPK signaling pathway.
  • Pathway Confirmation: To confirm the role of the p38 MAPK pathway, they used specific p38 inhibitors and agonists in their cell culture experiments.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • NAC as a Host Modulator, Not a Direct Killer: The study strongly suggests that NAC's primary benefit isn't directly killing M. abscessus (its MIC is very high), but rather by enhancing the host's ability to combat the infection. This is a crucial distinction for understanding its therapeutic role.
  • Targeting Oxidative Stress is Key: M. abscessus infection creates an oxidative stress environment that can impair host defenses. NAC, a known antioxidant, effectively counteracts this, which appears to be a central mechanism of its protective effect.
  • The ASK1-MKK3/6-p38 MAPK Axis is a Critical Target: The research pinpoints this specific inflammatory signaling pathway as a key mediator of NAC's beneficial effects. Downregulating this pathway seems to be how NAC achieves its anti-inflammatory and anti-bacterial outcomes.
  • Synergy with Existing Drugs: While NAC showed promise alone, its combination with CLR and CFZ also demonstrated improved outcomes, hinting at its potential as an adjunct therapy.

Key Results

  • Reduced Bacterial Load: NAC treatment led to a significant reduction in M. abscessus bacterial loads in both THP-1 macrophages (approximately 0.5 log10 CFU reduction) and in the lungs of infected nude mice.
  • Improved Lung Pathology: Histological analysis of mouse lungs showed reduced inflammation and better structural integrity in NAC-treated groups.
  • Modulation of Inflammatory Cytokines: NAC treatment led to the suppression of pro-inflammatory cytokines like IFN-γ and TNF-α, and a modest reduction in IL-10, while increasing overall antioxidant capacity and decreasing nitric oxide (NO) levels.
  • Downregulation of Key Signaling Proteins: Western blot analysis revealed decreased phosphorylation (indicating reduced activity) of ASK1, MKK3/6, and p38 MAPK in NAC-treated mice.
  • Pathway Validation: Using a p38 inhibitor mimicked NAC's protective effect, while a p38 agonist attenuated it, confirming the pathway's critical role.

Limitations and Future Work

The authors acknowledge several limitations:

  • Nude Mouse Model: While useful for studying innate immunity, nude mice lack T cells, which are crucial for adaptive immunity. Future studies should employ immunocompetent animal models and consider models that mimic clinical conditions like chronic lung disease.
  • In Vitro Concentration: The effective in vitro concentration of NAC (20-25 mM) is significantly higher than physiological levels. The authors suggest that time-compensation effects and in vivo bioavailability limitations might explain this discrepancy, and further research is needed to determine optimal therapeutic concentrations.
  • Clinical Translation Challenges: While promising, the clinical translation of NAC for M. abscessus infections faces challenges related to side-effect management and precise dosing. Future work should focus on optimizing dosing schedules, exploring novel delivery systems, and conducting multicenter clinical trials.
  • Mechanism Elucidation: Further research is needed to fully understand the specific role of MAPK pathways in M. abscessus infections and the precise balance of the ASK1-p38 pathway in host defense and immunopathology.

Summary updated

Abstract

(1) Background: The treatment of <i>Mycobacterium abscessus</i> (<i>M. abscessus</i>) infections resistant to clarithromycin (CLR) is highly challenging. Traditional non-tuberculous mycobacteria (NTM) chemotherapy may disturb the immune homeostasis of the host by increasing oxidative stress; therefore, host-directed immunotherapy is an alternative option for infections caused by <i>M. abscessus</i>. (2) Method: A clinical isolate of CLR-resistant <i>M. abscessus</i> was screened, and then the therapeutic effects of N-acetylcysteine (NAC) against CLR-resistant <i>M. abscessus</i> infection were evaluated in Tohoku Hospital Pediatrics-1 (THP-1) cells and murine models. RNA sequencing and Western blot were used to profile the protective immune responses induced by NAC. The contribution of candidate signaling pathways was confirmed by the corresponding inhibitor and agonist. (3) Results: NAC immunotherapy led to a significant reduction in bacterial loads both in THP-1 cells and murine infection models, which was associated with enhanced antioxidant effects and downregulation of apoptosis signal-regulating kinase 1 (ASK1)-mitogen-activated protein ki-nase/extracellular signal-regulated kinase 3/6 (MKK3/6)-p38 mitogen-activated protein kinase (MAPK)-mediated inflammatory immune responses. The inhibitor of p38 signaling mimicked the protective effect of NAC, while the agonist attenuated it, suggesting that the p38 pathway is crucial in NAC-mediated immune protection against <i>M. abscessus</i> infection. (4) Conclusion: Our study suggests that NAC could be used as a host-directed therapy agent against drug-resistant <i>M. abscessus</i> infection.
BibTeX
@inproceedings{yang2025n,
  author = {Shuqi Yang and Ying Zhang and Jinchuan Xu and Zhenyan Chen and Ren Yang and Yujiao Long and Xuejiao Huang and Juanxi Liu and Huan Huang and Shiqi Xie and Ruiqing Ma and Yajuan Dong and Xiao‐Yong Fan and Zhidong Hu and Feng Li},
  title = {{N-Acetylcysteine as a Host-Directed Therapy Against Clarithromycin-Resistant Mycobacterium abscessus}},
  booktitle = {Pathogens},
  year = {2025},
  doi = {10.3390/pathogens14040302},
}
Figure